Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort

OBJECTIVE: Benefits and risks of new therapies in Multiple Sclerosis (MS) must be balanced carefully and tailored to patients. We aimed to describe our experience with Fingolimod (FTY), correlating demographics, clinical and hematological features of the Relapsing MS (RMS) cohort with the occurring...

Descripción completa

Detalles Bibliográficos
Autores principales: Manni, Alessia, Direnzo, Vita, Iaffaldano, Antonio, Di Lecce, Valentina, Tortorella, Carla, Zoccolella, Stefano, Iaffaldano, Pietro, Trojano, Maria, Paolicelli, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651388/
https://www.ncbi.nlm.nih.gov/pubmed/29075564
http://dx.doi.org/10.1002/brb3.804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651388/
https://www.ncbi.nlm.nih.gov/pubmed/29075564
http://dx.doi.org/10.1002/brb3.804

Ejemplares similares